HTG Molecular Diagnostics Inc, Tucson, Ariz, recently introduced the Veri/O laboratory service, offering laboratory support for clients in biomarker research and companion diagnostic development.
The service formalizes and expands HTG’s traditional service offerings, including molecular profiling of retrospective cohorts to support the development of targeted and immunooncology therapies. The service will further support building custom research use only assays for early-stage clinical programs, and for the development of companion diagnostic assays for use in Phase III drug registration trials.
TJ Johnson, HTG Molecular Diagnostics.
“We are pleased with the increasing demand we are seeing from our biopharma customers for access to our HTG EdgeSeq technology as a service, which we believe marks growing acceptance of our technology by this important market segment,” says TJ Johnson, president and CEO of HTG Molecular Diagnostics.
“We also expect that it will drive placement of our automation platforms in contract research organizations and clinical labs when the biopharma development programs move into prospective trials or give rise to companion diagnostic tests,” Johnson adds. “We already have seen success deploying this model with our biopharma clients, enabling us to closely partner with them to meet the needs of their drug development programs.”
Chris Roberts, HTG Molecular Diagnostics.
According to Chris Roberts, senior vice president of corporate strategy and development at HTG Molecular Diagnostics, the company plans to offer services using new technologies and profiling panels as they become available. “We look forward to a version 2 chemistry offering in the Veri/O lab, starting with a small hotspot mutation assay, which we expect to expand to a larger panel to enable assessment of tumor mutation burden,” says Roberts.
For more information, visit HTG Molecular Diagnostics.
